Principal Investigator
Carmen Calfa
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20241035
Clinical Trial Summary
A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor- positive, HER2-positive breast cancer (ADEPT)
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647